Morgan Stanley
IDNA icon

Morgan Stanley’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Morgan Stanley’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Sell
81,337
-12,874
-14% -$386K ﹤0.01% 4657
2026
Q1 		$2.74M Buy
94,211
+31,693
+51% +$920K ﹤0.01% 4539
2025
Q4 		$1.64M Buy
62,518
+7,201
+13% +$185K ﹤0.01% 4934
2025
Q3 		$1.31M Sell
55,317
-76,328
-58% -$1.69M ﹤0.01% 5030
2025
Q2 		$2.7M Sell
131,645
-204,614
-61% -$4.12M ﹤0.01% 4515
2025
Q1 		$6.89M Buy
336,259
+16,242
+5% +$363K ﹤0.01% 3650
2024
Q4 		$7.24M Buy
320,017
+262,137
+453% +$6.29M ﹤0.01% 3669
2024
Q3 		$1.42M Sell
57,880
-70,757
-55% -$1.72M ﹤0.01% 4843
2024
Q2 		$2.97M Buy
128,637
+16,673
+15% +$390K ﹤0.01% 4300
2024
Q1 		$2.7M Sell
111,964
-5,965
-5% -$140K ﹤0.01% 4379
2023
Q4 		$2.71M Sell
117,929
-28,383
-19% -$570K ﹤0.01% 4329
2023
Q3 		$2.98M Sell
146,312
-38,971
-21% -$874K ﹤0.01% 4099
2023
Q2 		$4.33M Buy
185,283
+33,585
+22% +$806K ﹤0.01% 3879
2023
Q1 		$3.53M Sell
151,698
-69,977
-32% -$1.75M ﹤0.01% 4063
2022
Q4 		$5.58M Buy
221,675
+2,879
+1% +$77.3K ﹤0.01% 3654
2022
Q3 		$5.77M Buy
218,796
+57,126
+35% +$1.76M ﹤0.01% 3554
2022
Q2 		$4.67M Sell
161,670
-28,540
-15% -$852K ﹤0.01% 3831
2022
Q1 		$6.55M Buy
190,210
+4,966
+3% +$175K ﹤0.01% 3383
2021
Q4 		$8.12M Buy
185,244
+112,689
+155% +$5.33M ﹤0.01% 3166
2021
Q3 		$3.68M Buy
72,555
+43,718
+152% +$2.28M ﹤0.01% 4042
2021
Q2 		$1.5M Buy
28,837
+19,802
+219% +$929K ﹤0.01% 4840
2021
Q1 		$413K Buy
9,035
+8,929
+8,424% +$436K ﹤0.01% 5261
2020
Q4 		$5K Buy
+106
New +$4.58K ﹤0.01% 6769

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley's IDNA Position: Q2 2026 in Review

Morgan Stanley reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 14% in Q2 2026, selling an estimated $386K and leaving 81,337 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4657.

Morgan Stanley first reported a position in IDNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $8.12M in Q4 2021. 65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

  • Morgan Stanley held 81,337 shares of iShares Genomics Immunology and Healthcare ETF worth $2.75M as of Q2 2026.
  • Morgan Stanley sold 12,874 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $386K.
  • iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4657 holding.
  • Morgan Stanley first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's iShares Genomics Immunology and Healthcare ETF position peaked at $8.12M in Q4 2021.
  • 65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.